• In February 2026, Organon & Co. reported fourth-quarter 2025 sales of US$1,507 million, moving from net income of US$109 million a year earlier to a net loss of US$205 million, while also affirming a quarterly dividend of US$0.02 per share and issuing cautious 2026 revenue guidance of about US$6.2 billion.
• Alongside the weaker earnings and flat outlook, Organon secured FDA approval to extend Nexplanon’s use from three to five years and completed the Jada divestiture, steps that could reshape its product mix and debt profile over time.
• We’ll now examine how Organon’s earnings miss and cautious 2026 outlook affect the earlier investment narrative built around margin expansion.

Outshine the giants: these 28 early-stage AI stocks could fund your retirement.

Organon Investment Narrative Recap

To own Organon today, you have to believe its women’s health and biosimilar assets can offset pressure on aging brands and support gradual margin repair. The latest quarter’s loss, margin compression and flat 2026 revenue outlook keep the near term catalyst firmly tied to execution on cost savings and mix shift, while reinforcing the key risk around reliance on mature, price pressured products and policy sensitive Nexplanon demand.

Among the new announcements, the FDA’s approval to extend Nexplanon’s duration from three to five years stands out as most relevant. It directly intersects with the core thesis and risk around the Women’s Health franchise by potentially strengthening Nexplanon’s global role, even as U.S. policy headwinds and the 2025 revenue dip remind investors that the product’s contribution can be uneven and may take time to stabilize.

Yet beneath that headline, there is a less visible risk investors should be aware of around Organon’s continued exposure to...

Organon's narrative projects $6.5 billion revenue and $990.3 million earnings by 2028. This requires 1.2% yearly revenue growth and a $290.3 million earnings increase from $700.0 million today.

Uncover how Organon's forecasts yield a $9.36 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Before this miss, the most optimistic analysts were modeling revenue of about US$6.6 billion and earnings of roughly US$1.0 billion by 2028, which assumes much faster progress on issues like dependence on legacy and policy sensitive brands than the base case. This bullish view is clearly more optimistic than consensus, and after a quarter like this you may want to compare these different expectations and see which set of assumptions feels more realistic to you.

Explore 6 other fair value estimates on Organon - why the stock might be worth 32% less than the current price!

Build Your Own Organon Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Organon research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Organon research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Organon's overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.